Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents

Gastrointestinal Cancer Research

Volumn 4, Issue 1, 2011, Pages 15-21

  Zouhairi, Majed El ^a   Charabaty, Aline ^b   Pishvaian, Michael J ^a,c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; DASATINIB; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ISPINESIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MOTESANIB; OXALIPLATIN; PANITUMUMAB; SARACATINIB; SUNITINIB; TEMSIROLIMUS; VANDETANIB; VATALANIB;

ACNE; ADD ON THERAPY; ADJUVANT THERAPY; ALGORITHM; ARTERY THROMBOSIS; CANCER GROWTH; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CYTOPENIA; DEHYDRATION; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; FATIGUE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; STROKE; VOMITING;

EID: 79955636598     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, Ga: American Cancer Society, 2010.
2. Saltz LB: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
3. Goldberg, RM: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Grothey A: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
5. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-49, 2008
6. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin Oncol 33:S50-S56, 2006
7. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
8. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807, 2000
9. Lee JC, Chow NH, Wang ST, et al: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748-753, 2000
10. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
11. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
12. Ellis LM: Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33:S1-S7, 2006
13. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
14. Kesmodel SB, Ellis LM, Lin E, et al: Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BV) for colorectal cancer (CRC) liver metastases. 2007 Gastrointestinal Cancers Symposium, 2007 (abstr 234)
15. Gruenberger B, Tamandl D, Schueller J, et al: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835, 2008
16. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019, 2008
17. Wolmark N, Yothers G, O'Connell MJ, et al: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 27:, 2009 (abstr LBA4)
18. Prat A, Casado E, Cortes J: New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 13:5857-5866, 2007
19. Tang P, Cohen SJ, Bjarnason GA, et al: Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4027)
20. Hecht JR, Trarbach T, Jaeger E, et al: A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 23:16S, 2005 (abstr LBA3)
21. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007
22. Rosen LS, Kurzrock R, Mulay M, et al: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-76, 2007
23. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
24. Pishvaian MJ, Wang D, He R, Marshall JL: Epidermal Growth Factor Inhibitors, Encyclopedia of Cancer, Springer Berlin Heidelberg, 2008.
25. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207-1218, 2006
26. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
27. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
28. Gibson TB, Ranganathan A, Grothey A: Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29-31, 2006
29. Hecht JR, Mitchell E, Chidiac T, et al: Interim results from PACCE: irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as firstline treatment (tx) for metastatic colorectal cancer (mCRC), 2008 Gastrointestinal Cancers Symposium, 2008 (abstr 279)
30. Lievre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
31. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
32. Whitehead RP, McCoy S, Macdonald JS, et al: Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs 24:335-341, 2006
33. Abraham RT, Gibbons JJ: The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13:3109-3114, 2007
34. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
35. Tabernero J, Rojo F, Calvo E, et al: Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603-1610, 2008
36. Punt CJ, Boni J, Bruntsch U, et al: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003
37. Mackay HJ, Twelves CJ: Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7:554-562, 2007
38. Camidge DR, Gail Eckhardt S, Gore L, et al: A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 19:77-84, 2008
39. Carducci MA, Musib L, Kies MS, et al: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099, 2006
40. Resta LP, Ermisch S, Collins C, et al: Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer. J Clin Oncol 26(May 20 suppl): 2008 (abstr 3529)
41. Summy JM, Gallick GE: Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12:1398-1401, 2006
42. Tabernero J, Cervantes A, Hoekman K, et al: Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol 25:18S, 2007 (abstr 3520)
43. Wood KW, Cornwell WD, Jackson JR: Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 1:370-377, 2001
44. Luo L, Parrish CA, Nevins N, et al: ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 3:722-726, 2007
45. Chu QS, Holen KD, Rowinsky ED, et al: Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. J Clin Oncol 22:14S, 2004 (abstr 2078)
46. Burris HA, Lorusso P, Jones S, et al: Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. J Clin Oncol 22:128, 2004 (abstr 2004)